(AOF) – Valneva announced that the results of two Phase 2 clinical trials on its Lyme disease vaccine candidate, VLA15, have been published in the medical journal Lancet Infectious Diseases. The vaccine biotech specifies that these trials, as well as a third Phase 2 trial in pediatric participants, supported the design of the ongoing pivotal Phase 3 trial, “Vaccine Against Lyme for Outdoor Recreationists” (Valor) .
“We are pleased that these results are now accessible to the entire scientific community and those working to prevent infectious diseases,” said Juan Carlos Jaramillo, medical director of Valneva. “Lyme disease is the most common vector-borne infectious disease in North America and Europe, and we are excited about ongoing trials and progress toward potentially providing a vaccine against this need. medical not satisfied.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.
